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Abstract  
BACKGROUND: Alport syndrome is a genetic disease that progresses to chronic kidney failure, 
with X-linked, autosomal dominant or autosomal recessive type of inheritance. Women are 
generally carriers of the mutation and have a milder form of the disease. During pregnancy, they 
have an increased risk of impaired kidney function and preeclampsia. 
CASE PRESENTATION: A 27-year old woman, gravida 1, para 0, in her 23rd gestational week 
came to the outpatient unit of the University Clinic of Nephrology for the first time because of slowly 
progressing proteinuria and Alport syndrome. She was admitted to the gynaecological ward in her 
29th gw for proteinuria which increased from 3.8 g/day up to 20 g/day and the serum creatinine 
increased to 120- 150 micromol/l. She was delivered in the 30th gestational week due to obstetrical 
indications with a cesarian section and delivered a baby with a birth weight of 880 g. After delivery, 
proteinuria decreased to 2 g/d within 2 months and an angiotensin-converting enzyme inhibitor 
(ACEI) was started. Her second pregnancy, after 2 years, had an uneventful course and she 
delivered a healthy baby weighing 3000 g in the 39th week. Six months after the second delivery, 
her renal function remained normal and her proteinuria was 2 g/d.  
CONCLUSIONS: Pre-pregnancy counselling and frequent controls during pregnancy are necessary 
for women with Alport syndrome, as well as regular monitoring after delivery. Recent reports are 
more in favour of good pregnancy and nephrological outcomes in women with Alport syndrome 
when renal disease is not advanced. 
 
 
 
 
Introduction 
 
Alport syndrome is a genetic disease that 
progresses to chronic kidney failure and is 
characterised by persistent hematuria, proteinuria and 
progressive renal disease. It may be associated with 
hearing loss and ocular abnormalities
, 
but not all 
clinical characteristics are found in all.patients with 
Alport syndrome [1].  
It is associated with mutations in type IV 
collagen gene and may have an X-linked (mutation on 
COL4A5), autosomal dominant (mutation on COL4A3 
or COL4A4) or autosomal recessive type of 
inheritance (mutation on COL4A3 or COL4A4) [2]. 
Women are generally carriers of the mutation 
and have a milder form of the disease, with slow 
progression of the renal disease [3]. During 
pregnancy, they have an increased risk of impaired 
kidney function and preeclampsia [4]. There are only 
several case reports found in the literature on Alport 
syndrome and pregnancy. 
 
 
Case Presentation 
 
A 27-year old woman, gravida 1, para 0, in 
her 23
rd
 gestational week consulted at the outpatient 
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unit of the University Clinic of Nephrology in Skopje, 
Macedonia, for the first time, because of slowly 
progressive proteinuria.  
Her father was diagnosed with Alport 
syndrome with renal biopsy, had chronic kidney 
failure, was on a hemodialysis and died at the age of 
57. Her uncle also had Alport syndrome confirmed by 
biopsy and was on hemodialysis. The patient and her 
two sisters were diagnosed with Alport and renal 
biopsy was not done because of their positive family 
history. They were followed since their childhood for 
erythrocyturia and different levels of proteinuria, but 
with normal serum creatinine and no hypertension. 
Her older sister, who has only erythrocyturia and no 
proteinuria, had a successful pregnancy with a term 
birth of a child with slightly lower birthweight. Her 
younger sister has erythrocyturia and proteinuria 
above 4 g/d. Unfortunately, genetic analysis is not 
available in the country and was not done in our 
patient.  
Proteinuria was first registered in our patient 5 
years before her first pregnancy, at her age of 22 and 
was in the range of 0.4 – 0.8 g/d.  
 
First pregnancy  
When the patient consulted in the Department 
of Nephrology in the 23rd gw, she had higher serum 
creatinine for pregnancy, 89 micromol/l, and in the 
urine, there were 20-25 erythrocytes in the sediment - 
17% of which were dysmorphic. Her renal ultrasound 
revealed an ectopically placed right kidney and 
hypertrophy of her left kidney. She was started on 
Aspirin 100 mg from the onset of the pregnancy. The 
24-hour proteinuria was 0.6 g/dU and progressed over 
time, and hypoalbuminemia worsened. Her D-dimers 
in the 23rd gw were slightly increased and low-
molecular-weight heparin was started at a dose of 40 
g. 
In 26 the gw, intrauterine growth retardation 
(IUGR) was registered and the fetus was bio-
metrically equal to 23 rd gestational week. There was 
already an increased resistance index (RI) at the 
umbilical artery up to 0.71 and a verified notch in the 
left uterine artery. In the 29th gw, the fetus was bio-
metrically equal to 25th gw, with a notch in the right 
umbilical artery. Blood pressure was within normal.  
She was admitted to the gynaecological ward 
in her 29th gw for proteinuria which increased from 
3.8 g/day up to 20 g/day and the serum creatinine 
increased to 120- 150 micromoles/l. Her albumin was 
29-22 g/l and uric acid was 332 micromoles/l. Blood 
pressures increased up to 140/80 mm Hg and she 
was started on Methyldopa 500 mg and continued 
with 250 mg. She was started on a small dose of 
corticosteroids in order to stimulate lung maturation. 
She was delivered in the 30th gestational 
week due to obstetrical indications with a cesarian 
section and delivered a baby with a birth weight of 880 
g. The baby died within 7 days and autopsy showed 
that respiratory distress was the cause of death. 
After delivery, proteinuria decreased to 2 g/d 
within 2 months and angiotensin-converting enzyme 
inhibitor (ACEI) was started. Because of a persistent 
cough, she was switched to an angiotensin-receptor 
blocker (ARB), Losartan 25 mg/d and her proteinuria 
decreased to 0.8 g/d. Her blood pressure remained 
normal and serum creatinine was 70-83 micromol/l at 
the follow-up two years after delivery. 
 
Second pregnancy 
After two years of her first pregnancy, the 
patient became pregnant again, with a baseline 
proteinuria of 2 g/dU and serum creatinine 89 
micromol/l. Her second pregnancy was uneventful, 
with regular monthly checkups, her blood pressure 
was in normal range and her proteinuria increased 
from 2 g/d up to 3.5 g/d by the 39
th
 gestational week. 
Her serum albumin was 29 g/l at the 39
th
 gestational 
week and creatinine rose to 81 g/l. She delivered a 
healthy baby by cesarian section in her 39
th
 
gestational week. Six months after the second 
delivery, her renal function remained normal and her 
proteinuria was 2/d.  
 
 
Discussion  
 
Chronic kidney disease (CKD) used to be a 
contraindication for pregnancy. It is no longer 
considered to be so, yet if the kidney disease is in an 
advanced stage, it is more difficult for a patient to 
conceive and have a successful pregnancy [4].
 
In the 
management of CKD in pregnancy, it is more 
important to manage clinical features than to know the 
aetiology [5]. Intrauterine growth retardation and 
preterm birth, as well as the risk for worsened kidney 
disease, occur twice more often in pregnant women 
with the renal disease. The risk from decreased renal 
function in pregnancy should be considered 
separately from comorbidities that may aggravate the 
condition [6].
 
A case-control study has shown that 
when proteinuria is below 1 g/d, serum creatinine is 
below 110 micrograms/d, without hypertension, 
pregnancy did not have an adverse effect on long-
term kidney function [7].
 
 
Alport syndrome in women is generally a mild 
disease, but there is a wide variability of renal 
outcomes. It is suggested that in heterozygous 
females with Alport syndrome, inactivation of the X 
chromosome may be important for the severity of the 
disease. Tissue-specific distribution of an alternatively 
spliced COL4A5 isoform and non-random X 
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chromosome inactivation reflect phenotypic variation 
in heterozygous X-linked Alport syndrome [8].
 
 
In the first pregnancy, our patient had chronic 
kidney disease in stage 1 from the beginning of 
pregnancy (erythrocyturia, albuminuria). Her serum 
creatinine was within normal, proteinuria was below 1 
g/d and her blood pressure was normal so that an 
uneventful pregnancy was expected. Yet, worsening 
proteinuria and hypoalbuminemia were associated 
with intrauterine growth retardation and biometrically 
smaller fetus, and despite corticosteroids for lung 
maturation, and low-molecular weight protein 
prophylaxis, the fetus had birthweight of 880 g and 
died due to respiratory distress. In the following period 
after delivery, the patient was followed at regular 
intervals and proteinuria decreased due to ACEI. In 
her next pregnancy, proteinuria started from 2 g and 
at the end of the pregnancy it increased to 3.5 g/dU, 
yet it was not the reason for a pre-term delivery nor 
intrauterine growth retardation. After delivery, the 
patient's renal function did not deteriorate further.  
There are only several case reports on the 
outcomes of pregnancy in women with Alport 
syndrome. Previous reports showed that pregnancies 
in women with Alport syndrome ended with 
preeclampsia and worsened renal function. Matsuo 
described a case with higher proteinuria (1-2 g/d) and 
higher serum creatinine from the start of the 
pregnancy, which evolved into preeclampsia and 
worsened kidney function [9].
 
He speculated that 
preeclampsia is more frequent in women with Alport 
syndrome because type 4 collagen can be found in 
placental and renal vessels and in the case of a 
mutation in both sites, destruction may occur and a 
common antigen may be involved [10].
 
Still, the report 
by Matsubara showed that umbilical cord of a 
newborn from a mother with Alport had negative 
immunofluorescence staining for the alpha 5 chain of 
type IV collagen. A good pregnancy outcome is 
reported by Matsoubara [11, 12]
 
and Alessi [13].
 
Recent expert guidelines on Alport syndrome state 
that ACEI should be used between pregnancies 
because they are nephroprotective and that they 
would be beneficial for proteinuria, and other risk 
factors for renal failure progression in patients with 
Alport syndrome [14].  
The risk for preeclampsia and worsened renal 
disease is increased in pregnant women with Alport 
syndrome [15]. Recent reports present cases with 
more favourable outcomes in both autosomal 
dominant and recessive cases [16, 17]. 
Considering the outcomes of pregnancies in 
women with Alport syndrome, pre-pregnancy 
counselling and frequent controls during pregnancy 
are necessary, as well as regular monitoring after 
delivery. Prepregnancy counselling should include 
information for the parents on the risk for the 
syndrome in the child and offered a prenatal diagnosis 
in the fetus. Controls during pregnancy should be 
once monthly, once a week immediately after delivery 
and then once a month in the first six months, their 
frequency in the next period depending on the renal 
affection. Recent reports are more in favour of good 
outcomes of pregnancies in women with Alport 
syndrome when renal disease is not advanced.  
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